Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT
Pietro Merli,Sonata Jodele,Eleanor Cook,Kasiani C. Myers,Adam Lane,Samppa Ryhänen,Maria Pia Cefalo,Francesco Quagliarella,Stella M. Davies,Ashley Teusink-Cross,Paibel Aguayo-Hiraldo,Jessie L. Alexander,Paul Szabolcs,Mira Kohorst,Tiziana Corsetti,Franco Locatelli,Anthony Sabulski
DOI: https://doi.org/10.1038/s41409-024-02487-w
2024-12-05
Bone Marrow Transplantation
Abstract:Graft failure after allogeneic hematopoietic stem cell transplant (HSCT) leads to inferior overall survival (OS) and the only available treatment is re-transplantation [1]. Immune-mediated graft failure, termed graft rejection, occurs through a complex process involving massive cytokine activation and subsequent donor cell death [2]. Interferon gamma (IFNγ) and its downstream markers are particularly elevated in graft rejection and multiple prior studies report the essential contribution of IFNγ to graft rejection pathophysiology [3,4,5,6]. IFNγ blockade is therefore a rational therapy for study in graft rejection. We retrospectively collected data from 6 European and US transplant centers (Bambino Gesù Children's Hospital (OPBG), Helsinki University Central Hospital, Cincinnati Children's Hospital Medical Center (CCHMC), Children's Hospital of Los Angeles, Mayo Clinic, and Children's Hospital of Pittsburgh) who treated patients with emapalumab, an anti- IFNγ monoclonal antibody, with the aim of preventing or treating graft rejection. Patients at US centers were treated with 10 mg/kg/dose of emapalumab if they developed signs of graft rejection. This approach is termed "treatment." Emapalumab dosing was based on existing HLH literature which reports a range between 1–10 mg/kg [7, 8]. Patients who received 10 mg/kg in the initial HLH study tolerated the therapy well and higher dosing was notably associated with less adverse events than lower dosing, likely reflecting the benefit of IFNγ neutralization in those patients [7, 8]. HLH patients in a prior study showed a 30% reduction in CXCL9 on day 5 of therapy (emapalumab dose range, 1–3 mg/kg) [8]. Based on this observation, we chose 10 mg/kg dosing in the current study to achieve more rapid IFNγ neutralization in the setting of typically brisk graft failures. No maximum dose was used, however some patients receive slightly below or above 10 mg/kg based on emapalumab vial sizes and efforts to minimize drug waste (range: 8–11.3 mg/kg). All treated patients met 2 or more of the following criteria: 1) HLA mismatched donor and/or prior graft failure, 2) unexplained fever >39 °C (or >38 °C if prior history of graft failure) after HSCT, 3) absolute neutrophil count (ANC) decline after initial engraftment, 4) delayed neutrophil engraftment after HSCT, 5) real-time CXCL9 > 2.5 × the upper limit of normal (ULN). These criteria were based on prior graft failure publications and details of ANC changes in treated patients are shown in Table 1 [1, 3, 4]. Table 1 Patient demographics and outcomes following preemptive treatment (A) or prophylaxis (B) with emapalumab to prevent immune-mediated graft failure. Full size table
oncology,immunology,hematology,transplantation